Is TGTX or MRNA more profitable?

TG Therapeutics has a net margin of 65.95% compared to Moderna's net margin of -143.55%. TG Therapeutics' return on equity of 88.73% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 65.95% 88.73% 43.44% Moderna -143.55% -26.64% -19.32%

Does the media refer more to TGTX or MRNA?

In the previous week, Moderna had 12 more articles in the media than TG Therapeutics. MarketBeat recorded 24 mentions for Moderna and 12 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.89 beat Moderna's score of 0.82 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 11 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ROIV or TGTX?

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 3,005.09 -$299.77M -$0.60 N/A TG Therapeutics $616.29M 13.66 $447.18M $2.86 19.23

Does the media prefer ROIV or TGTX?

In the previous week, TG Therapeutics had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for TG Therapeutics and 5 mentions for Roivant Sciences. TG Therapeutics' average media sentiment score of 0.89 beat Roivant Sciences' score of 0.70 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BNTX or TGTX?

In the previous week, TG Therapeutics had 6 more articles in the media than BioNTech. MarketBeat recorded 12 mentions for TG Therapeutics and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.06 beat TG Therapeutics' score of 0.89 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, INSM or TGTX?

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 39.01 -$1.28B -$5.75 N/A TG Therapeutics $616.29M 13.66 $447.18M $2.86 19.23

Is INSM or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Insmed's net margin of -144.44%. TG Therapeutics' return on equity of 88.73% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% TG Therapeutics 65.95% 88.73% 43.44%

Does the media prefer INSM or TGTX?

In the previous week, Insmed had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 13 mentions for Insmed and 12 mentions for TG Therapeutics. Insmed's average media sentiment score of 0.94 beat TG Therapeutics' score of 0.89 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VTRS or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Viatris' net margin of -2.04%. TG Therapeutics' return on equity of 88.73% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% TG Therapeutics 65.95% 88.73% 43.44%

Does the media refer more to VTRS or TGTX?

In the previous week, TG Therapeutics had 9 more articles in the media than Viatris. MarketBeat recorded 12 mentions for TG Therapeutics and 3 mentions for Viatris. Viatris' average media sentiment score of 1.10 beat TG Therapeutics' score of 0.89 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TG Therapeutics (TGTX) Competitors

$55.01 -2.11 (-3.69%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$54.65 -0.36 (-0.65%)

As of 07/13/2026 07:51 PM Eastern

Compare

TGTX vs. MRNA, ROIV, BNTX, INSM, and VTRS

Should you buy TG Therapeutics stock or one of its competitors? MarketBeat compares TG Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TG Therapeutics include Moderna (MRNA), Roivant Sciences (ROIV), BioNTech (BNTX), Insmed (INSM), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does TG Therapeutics compare to Moderna?

TG Therapeutics (NASDAQ:TGTX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

TG Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.66	$447.18M	$2.86	19.23
Moderna	$1.94B	13.68	-$2.82B	-$8.15	N/A

TG Therapeutics has a net margin of 65.95% compared to Moderna's net margin of -143.55%. TG Therapeutics' return on equity of 88.73% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 12 more articles in the media than TG Therapeutics. MarketBeat recorded 24 mentions for Moderna and 12 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.89 beat Moderna's score of 0.82 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	11 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics presently has a consensus price target of $53.33, suggesting a potential downside of 3.05%. Moderna has a consensus price target of $38.27, suggesting a potential downside of 42.89%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

TG Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Moderna has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Summary

TG Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

TG Therapeutics has a net margin of 65.95% compared to Roivant Sciences' net margin of -3,629.19%. TG Therapeutics' return on equity of 88.73% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
TG Therapeutics	65.95%	88.73%	43.44%

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A
TG Therapeutics	$616.29M	13.66	$447.18M	$2.86	19.23

Roivant Sciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

Roivant Sciences currently has a consensus price target of $33.59, suggesting a potential downside of 2.66%. TG Therapeutics has a consensus price target of $53.33, suggesting a potential downside of 3.05%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, TG Therapeutics had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for TG Therapeutics and 5 mentions for Roivant Sciences. TG Therapeutics' average media sentiment score of 0.89 beat Roivant Sciences' score of 0.70 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

BioNTech has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

In the previous week, TG Therapeutics had 6 more articles in the media than BioNTech. MarketBeat recorded 12 mentions for TG Therapeutics and 6 mentions for BioNTech. BioNTech's average media sentiment score of 1.06 beat TG Therapeutics' score of 0.89 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TG Therapeutics has a net margin of 65.95% compared to BioNTech's net margin of -44.39%. TG Therapeutics' return on equity of 88.73% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
TG Therapeutics	65.95%	88.73%	43.44%

BioNTech currently has a consensus target price of $129.13, indicating a potential upside of 43.36%. TG Therapeutics has a consensus target price of $53.33, indicating a potential downside of 3.05%. Given BioNTech's stronger consensus rating and higher probable upside, equities research analysts plainly believe BioNTech is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

TG Therapeutics has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.02	-$1.29B	-$5.88	N/A
TG Therapeutics	$616.29M	13.66	$447.18M	$2.86	19.23

Summary

TG Therapeutics beats BioNTech on 10 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Insmed currently has a consensus price target of $211.00, suggesting a potential upside of 93.33%. TG Therapeutics has a consensus price target of $53.33, suggesting a potential downside of 3.05%. Given Insmed's stronger consensus rating and higher possible upside, research analysts clearly believe Insmed is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

58.6% of TG Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Insmed has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

In the previous week, Insmed had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 13 mentions for Insmed and 12 mentions for TG Therapeutics. Insmed's average media sentiment score of 0.94 beat TG Therapeutics' score of 0.89 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to Insmed's net margin of -144.44%. TG Therapeutics' return on equity of 88.73% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A
TG Therapeutics	$616.29M	13.66	$447.18M	$2.86	19.23

Summary

TG Therapeutics beats Insmed on 10 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, TG Therapeutics had 9 more articles in the media than Viatris. MarketBeat recorded 12 mentions for TG Therapeutics and 3 mentions for Viatris. Viatris' average media sentiment score of 1.10 beat TG Therapeutics' score of 0.89 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.9% of Viatris shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Viatris currently has a consensus target price of $17.50, indicating a potential upside of 6.77%. TG Therapeutics has a consensus target price of $53.33, indicating a potential downside of 3.05%. Given Viatris' higher possible upside, research analysts plainly believe Viatris is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

TG Therapeutics has a net margin of 65.95% compared to Viatris' net margin of -2.04%. TG Therapeutics' return on equity of 88.73% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
TG Therapeutics	65.95%	88.73%	43.44%

Viatris has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

TG Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.33	-$3.51B	-$0.26	N/A
TG Therapeutics	$616.29M	13.66	$447.18M	$2.86	19.23

Summary

TG Therapeutics beats Viatris on 12 of the 16 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TGTX vs. The Competition

Export

Metric	TG Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.74B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	19.23	20.85	27.15	24.26
Price / Sales	13.66	314.01	587.92	117.88
Price / Cash	20.39	61.98	29.22	49.36
Price / Book	13.48	8.49	10.75	6.29
Net Income	$447.18M	$23.83M	$3.58B	$330.66M
7 Day Performance	-5.25%	-3.56%	-2.07%	-1.32%
1 Month Performance	11.09%	6.31%	3.31%	-0.64%
1 Year Performance	41.34%	48.30%	26.35%	19.08%

TG Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TGTX TG Therapeutics	3.1303 of 5 stars	$55.01 -3.7%	$53.33 -3.0%	+48.4%	$8.74B	$616.29M	19.23	290	Analyst Forecast
MRNA Moderna	1.8577 of 5 stars	$81.80 +2.6%	$37.13 -54.6%	+99.2%	$31.65B	$1.94B	N/A	4,700	Gap Down
ROIV Roivant Sciences	1.544 of 5 stars	$35.39 +0.7%	$33.59 -5.1%	+203.8%	$25.27B	$8.26M	N/A	860
BNTX BioNTech	4.5224 of 5 stars	$93.93 -3.7%	$129.56 +37.9%	-20.2%	$24.67B	$3.25B	N/A	7,807	Positive News
INSM Insmed	4.0914 of 5 stars	$111.54 -0.1%	$211.86 +89.9%	+11.2%	$24.19B	$606.42M	N/A	1,664	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TGTX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TG Therapeutics (TGTX) Competitors

TGTX vs. MRNA, ROIV, BNTX, INSM, and VTRS

How does TG Therapeutics compare to Moderna?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Summary

How does TG Therapeutics compare to BioNTech?

Summary

How does TG Therapeutics compare to Insmed?

Summary

How does TG Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TG Therapeutics (TGTX) Competitors

TGTX vs. MRNA, ROIV, BNTX, INSM, and VTRS

How does TG Therapeutics compare to Moderna?

Do insiders and institutionals hold more shares of TGTX or MRNA?

Which has higher earnings & valuation, TGTX or MRNA?

Is TGTX or MRNA more profitable?

Does the media refer more to TGTX or MRNA?

Do analysts recommend TGTX or MRNA?

Which has more risk and volatility, TGTX or MRNA?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Is ROIV or TGTX more profitable?

Do institutionals and insiders have more ownership in ROIV or TGTX?

Which has stronger earnings and valuation, ROIV or TGTX?

Which has more risk and volatility, ROIV or TGTX?

Do analysts rate ROIV or TGTX?

Does the media prefer ROIV or TGTX?

Summary

How does TG Therapeutics compare to BioNTech?

Which has more volatility and risk, BNTX or TGTX?

Does the media favor BNTX or TGTX?

Do insiders and institutionals believe in BNTX or TGTX?

Is BNTX or TGTX more profitable?

Do analysts rate BNTX or TGTX?

Which has higher valuation and earnings, BNTX or TGTX?

Summary

How does TG Therapeutics compare to Insmed?

Do analysts rate INSM or TGTX?

Do insiders and institutionals have more ownership in INSM or TGTX?

Which has more risk & volatility, INSM or TGTX?

Does the media prefer INSM or TGTX?

Is INSM or TGTX more profitable?

Which has stronger valuation and earnings, INSM or TGTX?

Summary

How does TG Therapeutics compare to Viatris?

Does the media refer more to VTRS or TGTX?

Do insiders & institutionals hold more shares of VTRS or TGTX?

Do analysts recommend VTRS or TGTX?

Is VTRS or TGTX more profitable?

Which has more risk & volatility, VTRS or TGTX?

Which has better valuation & earnings, VTRS or TGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools